Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
Patients aged 18 and older with moderate to severe orbitopathy;
Patients followed in endocrinology with the goal of achieving euthyroidism;
Corticosteroid-resistant patients: patients who have received at least 3 weeks of treatment with 500 mg weekly corticosteroid boluses and have not shown improvement in the clinical activity score (CAS);
Corticosteroid-dependent patients: relapse with a CAS of 3 or higher when decreasing or stopping corticosteroid therapy;
Patients who have undergone bone or fat decompression surgery;
Patients with severe corneal involvement (Grade B or C; NO SPECS classification);
Patients with optic neuropathy (Grade B and C; NO SPECS classification);
Patients who have received 1 gram corticosteroid boluses for dysthyroid orbitopathy;